Yousaf Abid Mehmood, Qadeer Alina, Raza Syed Atif, Chohan Tahir Ali, Shahzad Yasser, Din Fakhar Ud, Khan Ikram Ullah, Hussain Talib, Alvi Muhammad Nadeem, Mahmood Tariq
Drug Delivery Research Group, Department of Pharmacy, COMSATS University Islamabad, Lahore, Pakistan.
Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan.
Polim Med. 2019 Jan-Jun;49(1):35-43. doi: 10.17219/pim/111887.
Poorly water-soluble drugs do not dissolve well in aqueous-based gastrointestinal fluid; therefore, they are not well absorbed. Thus, employing a suitable solubility enhancing technique is necessary for such a drug. Drug/HP‑β‑CD complexation is a promising way to improve solubility and dissolution of a poorly water-soluble drug. Levodropropizine was used as a model drug in this study.
The purpose of this research was to enhance the aqueous solubility and dissolution rate of levodropropizine by employing the inclusion complexation technique.
A microparticle formulation was prepared from levodropropizine and hydroxypropyl-β-cyclodextrin (HP‑β‑CD) in a 1:1 molar ratio through the spray-drying technique. The host-guest relationship between levodropropizine and HP‑β‑CD was also investigated using the molecular docking computational methodology. The aqueous solubility and dissolution rate of levodropropizine in formulations were assessed and compared with those of the drug alone. X-ray diffraction (XRD), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR) were applied for the solid-state characterization of the prepared samples.
According to the research outcomes, the levodropropizine/HP‑β‑CD formulation had enhanced the aqueous solubility (351.12 ±13.26 vs 92.76 ±5.00 mg/mL) and dissolution rate (97.83 ±3.36 vs 3.12 ±1.76% in 10 min) of levodropropizine, compared to the plain drug powder. The levodropropizine/ HP‑β‑CD formulation had converted the crystalline drug into its amorphous counterpart. Furthermore, no covalent interaction was found to exist between levodropropizine and HP‑β‑CD. The spray-dried particles were discrete. Each particle had a shriveled appearance.
The levodropropizine/HP‑β‑CD formulation is, therefore, recommended for the more effective administration of levodropropizine through the oral route.
水溶性差的药物在水性胃肠液中溶解不佳;因此,它们的吸收也不好。因此,对于这类药物,采用合适的增溶技术是必要的。药物/羟丙基-β-环糊精(HP-β-CD)络合是提高水溶性差的药物溶解度和溶出度的一种有前景的方法。本研究以左羟丙哌嗪为模型药物。
本研究的目的是通过包合络合技术提高左羟丙哌嗪的水溶性和溶出速率。
通过喷雾干燥技术,以1:1的摩尔比由左羟丙哌嗪和羟丙基-β-环糊精(HP-β-CD)制备微粒制剂。还使用分子对接计算方法研究了左羟丙哌嗪与HP-β-CD之间的主客体关系。评估了左羟丙哌嗪在制剂中的水溶性和溶出速率,并与单独的药物进行比较。采用X射线衍射(XRD)、差示扫描量热法(DSC)、扫描电子显微镜(SEM)和傅里叶变换红外光谱(FTIR)对制备的样品进行固态表征。
根据研究结果,与普通药物粉末相比,左羟丙哌嗪/HP-β-CD制剂提高了左羟丙哌嗪的水溶性(351.12±13.26对92.76±5.00mg/mL)和溶出速率(10分钟时为97.83±3.36对3.12±1.76%)。左羟丙哌嗪/HP-β-CD制剂将结晶药物转化为无定形药物。此外,未发现左羟丙哌嗪与HP-β-CD之间存在共价相互作用。喷雾干燥的颗粒是离散的。每个颗粒外观皱缩。
因此,推荐左羟丙哌嗪/HP-β-CD制剂用于左羟丙哌嗪更有效的口服给药。